Literature DB >> 8903331

Autoimmunity associated with TGF-beta1-deficiency in mice is dependent on MHC class II antigen expression.

J J Letterio1, A G Geiser, A B Kulkarni, H Dang, L Kong, T Nakabayashi, C L Mackall, R E Gress, A B Roberts.   

Abstract

The progressive inflammatory process found in transforming growth factor beta1 (TGF-beta1)-deficient mice is associated with several manifestations of autoimmunity, including circulating antibodies to nuclear antigens, immune complex deposition, and increased expression of both class I and class II major histocompatibility complex (MHC) antigens. The contribution of MHC class II antigens to the genesis of this phenotype has been determined by crossing the TGF-beta1-null [TGF-beta1(-/-)] genotype into the MHC class II-deficient [MHC-II(-/-)] background. Mice homozygous for both the TGF-beta1 null allele and the class II null allele [TGF-beta1(-/-);MHC-II(-/-)] are without evidence of inflammatory infiltrates, circulating autoantibodies, or glomerular immune complex deposits. Instead, these animals exhibit extensive extramedullary hematopoiesis with progressive splenomegaly and adenopathy, surviving only slightly longer than TGF-beta1(-/-);MHC-II(+/+) mice. The role of CD4+ T cells, which are also absent in MHC class II-deficient mice, is directly demonstrated through the administration of anti-CD4 monoclonal antibodies in class II-positive, TGF-beta1(-/-) mice. The observed reduction in inflammation and improved survival emphasize the significance of CD4+ cells in the pathogenesis of the autoimmune process and suggest that the additional absence of class II antigens in TGF-beta1(-/-);MHC-II(-/-) mice may contribute to their extreme myeloid metaplasia. Thus, MHC class II antigens are essential for the expression of autoimmunity in TGF-beta1-deficient mice, and normally may cooperate with TGF-beta1 to regulate hematopoiesis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8903331      PMCID: PMC507656          DOI: 10.1172/JCI119017

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  46 in total

Review 1.  Transforming growth factor-beta1-deficient mice: identification of isoform-specific activities in vivo.

Authors:  J J Letterio; A B Roberts
Journal:  J Leukoc Biol       Date:  1996-06       Impact factor: 4.962

2.  A rationally designed CD4 analogue inhibits experimental allergic encephalomyelitis.

Authors:  B A Jameson; J M McDonnell; J C Marini; R Korngold
Journal:  Nature       Date:  1994-04-21       Impact factor: 49.962

3.  Transforming growth factor-beta inhibits E-selectin expression on human endothelial cells.

Authors:  J R Gamble; Y Khew-Goodall; M A Vadas
Journal:  J Immunol       Date:  1993-05-15       Impact factor: 5.422

4.  Transforming growth factor beta 1 repression of the HLA-DR alpha gene is mediated by conserved proximal promoter elements.

Authors:  A M Reimold; C J Kara; J W Rooney; L H Glimcher
Journal:  J Immunol       Date:  1993-10-15       Impact factor: 5.422

5.  TGF-beta is a bidirectional modulator of cytokine receptor expression on murine bone marrow cells. Differential effects of TGF-beta 1 and TGF-beta 3.

Authors:  S E Jacobsen; F W Ruscetti; A B Roberts; J R Keller
Journal:  J Immunol       Date:  1993-11-01       Impact factor: 5.422

6.  Transforming growth factor beta 1 (TGF-beta 1) controls expression of major histocompatibility genes in the postnatal mouse: aberrant histocompatibility antigen expression in the pathogenesis of the TGF-beta 1 null mouse phenotype.

Authors:  A G Geiser; J J Letterio; A B Kulkarni; S Karlsson; A B Roberts; M B Sporn
Journal:  Proc Natl Acad Sci U S A       Date:  1993-11-01       Impact factor: 11.205

Review 7.  Transforming growth factor beta: a matter of life and death.

Authors:  N L McCartney-Francis; S M Wahl
Journal:  J Leukoc Biol       Date:  1994-03       Impact factor: 4.962

8.  Autoimmune manifestations in the transforming growth factor-beta 1 knockout mouse.

Authors:  L Yaswen; A B Kulkarni; T Fredrickson; B Mittleman; R Schiffman; S Payne; G Longenecker; E Mozes; S Karlsson
Journal:  Blood       Date:  1996-02-15       Impact factor: 22.113

9.  Early-onset multifocal inflammation in the transforming growth factor beta 1-null mouse is lymphocyte mediated.

Authors:  R J Diebold; M J Eis; M Yin; I Ormsby; G P Boivin; B J Darrow; J E Saffitz; T Doetschman
Journal:  Proc Natl Acad Sci U S A       Date:  1995-12-19       Impact factor: 11.205

10.  Transforming growth factor beta enhances integrin expression and type IV collagenase secretion in human monocytes.

Authors:  S M Wahl; J B Allen; B S Weeks; H L Wong; P E Klotman
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-15       Impact factor: 11.205

View more
  55 in total

1.  TGF-beta1 null mutation leads to CD154 upregulated expression in affected tissues.

Authors:  T Nakabayashi; K M Sakata; A Sakata; L Kong; C A Lau; J J Letterio; N Vela-Roch; N Talal; H Dang
Journal:  Inflammation       Date:  2001-04       Impact factor: 4.092

Review 2.  The changing role of TGFβ in healthy, ageing and osteoarthritic joints.

Authors:  Peter M van der Kraan
Journal:  Nat Rev Rheumatol       Date:  2017-02-02       Impact factor: 20.543

Review 3.  Regulatory T cells and immune tolerance in the intestine.

Authors:  Oliver J Harrison; Fiona M Powrie
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-07-01       Impact factor: 10.005

4.  Lethal effect of CD3-specific antibody in mice deficient in TGF-beta1 by uncontrolled flu-like syndrome.

Authors:  Sylvain Perruche; Pin Zhang; Takashi Maruyama; Jeffrey A Bluestone; Philippe Saas; WanJun Chen
Journal:  J Immunol       Date:  2009-06-26       Impact factor: 5.422

Review 5.  Adrenergic Modulation of Hematopoiesis.

Authors:  Georges J M Maestroni
Journal:  J Neuroimmune Pharmacol       Date:  2019-02-14       Impact factor: 4.147

Review 6.  Immunoregulation by members of the TGFβ superfamily.

Authors:  WanJun Chen; Peter Ten Dijke
Journal:  Nat Rev Immunol       Date:  2016-11-25       Impact factor: 53.106

Review 7.  Induced and natural regulatory T cells in the development of inflammatory bowel disease.

Authors:  Christopher G Mayne; Calvin B Williams
Journal:  Inflamm Bowel Dis       Date:  2013-07       Impact factor: 5.325

8.  Proteomic Analysis of CSF from Patients with Leptomeningeal Melanoma Metastases Identifies Signatures Associated with Disease Progression and Therapeutic Resistance.

Authors:  Inna Smalley; Vincent Law; Clayton Wyatt; Brittany Evernden; Bin Fang; John M Koomen; Eric A Welsh; Robert J B Macaulay; Peter A Forsyth; Keiran S M Smalley
Journal:  Clin Cancer Res       Date:  2020-01-10       Impact factor: 12.531

9.  Loss of TGF-beta signaling contributes to autoimmune pancreatitis.

Authors:  K B Hahm; Y H Im; C Lee; W T Parks; Y J Bang; J E Green; S J Kim
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

Review 10.  TGFbeta1 and Treg cells: alliance for tolerance.

Authors:  Ramireddy Bommireddy; Thomas Doetschman
Journal:  Trends Mol Med       Date:  2007-10-30       Impact factor: 11.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.